R. A. Coleman, M. Johnson, A. T. Nials and C. J. Vardey, “Exosites: Their Current Status, and Their Relevance to the Duration of Action of Long-Acting β2-Adrenoceptor Agonists,” Trends in Pharmacological Sciences, Vol. 17, No. 9, 1996, pp. 324-330.
http://dx.doi.org/10.1016/0165-6147(96)10040-7

has been cited by the following article:

• TITLE: Evidence for a Non-β2-Adrenoceptor Binding Site in Human Lung Tissue for a Subset of β2-Adrenoceptor Agonists

  AUTHORS: Robert J. Slack

  KEYWORDS: β2-Adrenoceptor; Radioligand Binding; Human Lung; Tissue Binding Site

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.5 No.1, January 9, 2014

  ABSTRACT: The aim of this study was to compare the binding profile of a range of β2-adrenoceptor (β2-AR) agonists and antagonists in human lung tissue. Radioligand saturation and competition binding experiments were performed by filtration with a β2-AR antagonist ([3H]propranolol) or agonist ([3H]vilanterol) radioligand and membrane fragments generated from lung parenchyma in the presence of 100 μM guanosine 5’-[β,γ-imido]triphosphate (Gpp(NH)p). In membranes prepared from human lung parenchyma, carmoterol, formoterol, ICI118551, propranolol and salbutamol resulted in inhibition of [3H]vilanterol binding to levels that were significantly different from indacaterol, salmeterol and vilanterol (ANOVA, Bonferroni post-test, P 3H]vilanterol binding to levels that were not significantly different from vilanterol (ANOVA, Bonferroni post-test, P > 0.05). Indacaterol, salmeterol and vilanterol resulted in full inhibition of [3H]propranolol binding to levels not significantly different from ICI118551 (ANOVA, Bonferroni post-test, P > 0.05). Indacaterol, salmeterol and vilanterol bind to an additional site in human lung parenchyma membranes that is distinct from the β2-AR.